A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Trial Profile

A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Umbralisib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
  • Indications Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Oesophageal cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors TG Therapeutics Inc
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 28 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Nov 2017.
    • 28 Jun 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top